CTIS2022-503133-54-00
Recruiting
Phase 1
A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engaging Receptor Molecule (TCER®) targeting PRAME, in Patients with Recurrent and/or Refractory Solid Tumors - IMA402-101
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Solid Tumors
- Sponsor
- Immatics Biotechnologies GmbH
- Enrollment
- 155
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients \= 18 years old, Pathologically confirmed and documented advanced and/or metastatic solid tumors with defined PRAME tumor target expression, Confirmed HLA status, Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1\.1\), Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1, Patients must have received or not be eligible for all available indicated standard\-of\-care treatments, Adequate baseline hematologic, renal and hepatic function, acceptable coagulation status
Exclusion Criteria
- •Other active malignancies that require treatment or that might interfere with the trial endpoints, Patient is pregnant or is breastfeeding, History of hypersensitivity to components of IMA402 or rescue medications, The patient has concurrent severe and/or uncontrolled medical disease. Any other health condition that would, in the investigator’s judgement, contraindicate the patient’s participation in the clinical trial because of safety concerns or compliance with clinical trial procedures, Patients with active brain metastases
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
A study to investigate small mobile stem cells (SMS cells) in participants aged 39 to 69 years with chronic obstructive pulmonary disease.Chronic Obstructive Pulmonary DiseaseRespiratory - Chronic obstructive pulmonary diseaseACTRN12624001140549SMSbiotech Australia Pty Ltd18
Active, not recruiting
Phase 1
A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients with Plasma Cell Disorders Including Multiple MyelomaRelapsed or refractory Multiple Myeloma (r/r MM)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2020-003414-12-DEHeidelberg Pharma AG130
Recruiting
Phase 1/2
A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients with Plasma Cell Disorders Including Multiple Myeloma2024-515273-10-00Heidelberg Pharma AG71
Active, not recruiting
Phase 1
Clinical trial to evaluate the safety and immune activation of DCVAC/PCa and ONCOS-102 in men with metastatic prostate cancer.advanced metastatic castration-resistant prostate cancerMedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-004314-15-CZSOTIO a.s.15
Active, not recruiting
Phase 1
Tuberculosis Vaccine in Healthy Indian Adults.CTRI/2024/01/061474Bharat Biotech International Limited